ExosomeDx: Exosome Based Liquid Biopsies for Prostate Cancer
A standalone, exosome-based prostate cancer test delivering a unique data point to help guide the prostate biopsy decision. The ExoDx Prostate test has been included in the NCCN Guidelines since 2019 for early detection of prostate cancer. The ExoDx Prostate test is independent of PSA and other standard of care (SOC) information. For TeleMedicine visits, check out the At-Home Collection Kit! Leverages the power of exosomes to detect disease earlier in the progression of prostate cancer.
This company is:
Verified
Biomarker Discovery: ExosomeDx
Proprietary Platforms used for Biomarker Discovery | Exosome Diagnostics proprietary platform | When to Start | Schedule a meeting | Learn more about research and clinical applications | Our biomarker discovery capabilities are broad and provide the ability to analyze and quantitatively measure RNAs, cfDNA, and specific cell or tissue types using our proprietary platforms:
Verified
Exosome Enrichment Capabilities: ExosomeDx
Exosome Enrichment | Exosome Depletion | Schedule a meeting | Stay in touch with ExosomeDx
Verified
Companion Diagnostics (CDx) and Clinical Trial Support: ExosomeDx
Drug Development | Diagnostic Development | Tissue & Additional Services | Schedule a meeting
View all products
Keywords
Industries
Where is Exosome Diagnostics located?
The company Exosome Diagnostics is located in New York, New York, United States. It's worth noting that the company may has more corporate locations
How many employees does Exosome Diagnostics approximately have?
As of the latest available information Exosome Diagnostics has around 101-250 employees worldwide.
When was Exosome Diagnostics founded?
Exosome Diagnostics was founded in 2008
In which industries does Exosome Diagnostics mainly work?
The company Exosome Diagnostics has it's main focus in the industries of Biotechnology, Science and Engineering, Health Care
What is the current company status of Exosome Diagnostics?
Based on the founding year and the amount of employees the company Exosome Diagnostics seems to be a Medium-Sized Company at the current state. Note that over time that status can change
Biological Dynamics
United States
51-100 Employees
2010
ExBiome
Netherlands
1-10 Employees
2015
Ashion Analytics
United States
11-50 Employees
2014
Chip Diagnostics
United States
1-10 Employees
2016
LynxDx
United States
1-10 Employees
2015
Gregor Diagnostics
United States
1-10 Employees
2016
MDxHealth
Belgium
51-100 Employees
2003
Nanostics
Canada
11-50 Employees
2017
Topics which have been searched by others and may be interesting for you:
